Literature DB >> 17901797

Routine laboratory testing data for surveillance of rotavirus hospitalizations to evaluate the impact of vaccination.

Manish M Patel1, Jacqueline E Tate, Rangaraj Selvarangan, Irini Daskalaki, Mary Anne Jackson, Aaron T Curns, Susan Coffin, Barbara Watson, Richard Hodinka, Roger I Glass, Umesh D Parashar.   

Abstract

OBJECTIVE: The recent implementation of a rotavirus vaccination program in the United States makes it imperative to assess the impact of immunization on the incidence of severe rotavirus disease leading to hospitalization. Active surveillance for laboratory-confirmed rotavirus hospitalizations is the ideal approach for surveillance, but requires substantial resources to implement. We examined laboratory and hospital discharge data for 2 tertiary care pediatric hospitals to assess the utility of routine laboratory testing data for surveillance of rotavirus gastroenteritis and to estimate rotavirus disease burden.
DESIGN: We obtained all discharge records of hospitalizations for acute gastroenteritis among children <5 years of age at Children's Mercy Hospital (CMH), Kansas City, from July 2000 to June 2005 and at Children's Hospital of Philadelphia (CHOP) from July 2004 to June 2006. We linked these discharge records to laboratory results of rotavirus testing to evaluate epidemiologic differences in children who were tested and not tested for rotavirus and to estimate overall rotavirus burden by extrapolating clinical testing results to the untested group.
RESULTS: At CMH, of the 3702 children with acute gastroenteritis, 69% (n = 2552) were discharged during the winter (January through May) months, when rotavirus is most common. Similarly, at CHOP, 62% (n = 779) of the 1261 gastroenteritis discharges occurred during the winter months. During these months, 47% (n = 1197 of 2552) of the discharges at CMH and 56% (n = 438 of 779) of the discharges at CHOP were tested for rotavirus and of those tested, 71% (n = 853 of 1197) and 55% (n = 242 of 438) were positive, respectively. At both hospitals, children with and without rotavirus testing had similar gender and race/ethnicity, but the rate of testing differed by age at CHOP and by month of admission at CMH. After adjusting for these differences, we estimate that 56%-70% of winter and 34%-48% of year-round gastroenteritis in children <5 years can be attributable to rotavirus. Overall, 3%-5% of all hospitalizations in children <5 years of age were caused by rotavirus.
CONCLUSIONS: Sentinel hospitals where a large proportion of children hospitalized for gastroenteritis are routinely tested for rotavirus could provide a useful and cost-efficient platform to complement ongoing active surveillance efforts to evaluate the impact of rotavirus vaccination. The data reaffirm the substantial burden of rotavirus hospitalizations in US children and the potential health benefits of vaccination.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901797     DOI: 10.1097/INF.0b013e31812e52fd

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  9 in total

1.  Direct, indirect, total, and overall effectiveness of the rotavirus vaccines for the prevention of gastroenteritis hospitalizations in privately insured US children, 2007-2010.

Authors:  Catherine A Panozzo; Sylvia Becker-Dreps; Virginia Pate; David J Weber; Michele Jonsson Funk; Til Stürmer; M Alan Brookhart
Journal:  Am J Epidemiol       Date:  2014-02-26       Impact factor: 4.897

2.  Epidemiological and clinical features of rotavirus among children younger than 5 years of age hospitalized with acute gastroenteritis in Northern Italy.

Authors:  Gianvincenzo Zuccotti; Fabio Meneghin; Dario Dilillo; Luisa Romanò; Roberta Bottone; Cecilia Mantegazza; Roberto Giacchino; Roberto Besana; Giuseppe Ricciardi; Andrea Sterpa; Nicola Altamura; Massimo Andreotti; Giovanni Montrasio; Luigi Macchi; Anna Pavan; Sara Paladini; Alessandro Zanetti; Giovanni Radaelli
Journal:  BMC Infect Dis       Date:  2010-07-22       Impact factor: 3.090

3.  Estimating the Effectiveness of Rotavirus Vaccine Schedules.

Authors:  Anne M Butler; Alexander Breskin; John M Sahrmann; M Alan Brookhart
Journal:  Epidemiology       Date:  2021-07-01       Impact factor: 4.860

4.  Importance of ICD-10 coding directive change for acute gastroenteritis (unspecified) for rotavirus vaccine impact studies: illustration from a population-based cohort study from Ontario, Canada.

Authors:  Sarah E Wilson; Shelley L Deeks; Laura C Rosella
Journal:  BMC Res Notes       Date:  2015-09-15

5.  Population-Level Impact of Ontario's Infant Rotavirus Immunization Program: Evidence of Direct and Indirect Effects.

Authors:  Sarah E Wilson; Laura C Rosella; Jun Wang; Nicole Le Saux; Natasha S Crowcroft; Tara Harris; Shelly Bolotin; Shelley L Deeks
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

6.  A Rapid Epidemiological Tool to Measure the Burden of Norovirus Infection and Disease in Resource-Limited Settings.

Authors:  Daniel Olson; Molly M Lamb; Maria Renee Lopez; M Alejandra Paniagua-Avila; Alma Zacarias; Gabriela Samayoa-Reyes; Celia Cordon-Rosales; Edwin J Asturias
Journal:  Open Forum Infect Dis       Date:  2017-03-17       Impact factor: 3.835

7.  10-Year Rotavirus Infection Surveillance: Epidemiological Trends in the Pediatric Population of Perugia Province.

Authors:  Chiara de Waure; Laura Sarnari; Manuela Chiavarini; Giovanni Ianiro; Marina Monini; Anna Alunno; Barbara Camilloni
Journal:  Int J Environ Res Public Health       Date:  2020-02-05       Impact factor: 3.390

8.  Norovirus disease in the United States.

Authors:  Aron J Hall; Ben A Lopman; Daniel C Payne; Manish M Patel; Paul A Gastañaduy; Jan Vinjé; Umesh D Parashar
Journal:  Emerg Infect Dis       Date:  2013-08       Impact factor: 6.883

9.  Effectiveness of rotavirus vaccine in preventing severe gastroenteritis in young children according to socioeconomic status.

Authors:  Virginie Gosselin; Mélissa Généreux; Arnaud Gagneur; Geneviève Petit
Journal:  Hum Vaccin Immunother       Date:  2016-07-01       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.